Jane Street Group, LLC Passage Bio, Inc. Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.96 - $1.88 $4,124 - $8,076	4,296 Added 35.01%	16,568 $15,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $5,766 - $8,051	-5,440 Reduced 30.71%	12,272 $16,000
Q3 2022 Nov 14, 2022	BUY	$1.28 - $2.48 $22,671 - $43,925	17,712 New	17,712 $22,000
Q4 2021 Feb 15, 2022	SELL	$6.24 - $10.2 $71,129 - $116,269	-11,399 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$9.73 - $15.52 $110,912 - $176,912	11,399 New	11,399 $114,000

Q4 2020 Feb 17, 2021	SELL	$14.28 - $29.73 $252,813 - $526,339	-17,704 Closed	0 $0
Q3 2020 Nov 17, 2020	BUY	$12.39 - $26.15 $72,840 - $153,735	5,879 Added 49.72%	17,704 $232,000
Q2 2020 Aug 17, 2020	BUY	$14.59 - $36.07 $172,526 - $426,527	11,825 New	11,825 $323,000

33M

20.3K

500

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $54.5M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.